Cancer stem cells are new vistas for predicting the course of breast cancer

Despite progress in treating breast cancer (BC) using a combined approach in view of morphological findings, distant metastases may develop in 30–90 % of patients with primary BC even at its early stages. The cancer stem cell (CSC) theory is one of the versions that could at least partially explain therapeutic inefficiency. This theory suggests that cancer may occur and arise from a small proportion of stem cells that are able to induce tumor growth and to affect resistance to chemoand radiotherapy. CSCs were identified in different malignant tumors, including BC, cancer of the prostate, colon, pancreas, head and neck, melanoma, and multiple myelomas. 

This investigation analyzed aldehyde dehydrogenase type 1 (ALDH1) expression in patients with BC. Moreover, the investigators examined the relationship between this marker and the clinical and pathological features of BC. The investigation enrolled 83 locally advanced BC (T1–4N0–3M0) patients treated in 2005 to 2009. To detect CSCs, 83 histological specimens obtained at biopsy in BC patients treated at the Russian Research Center for Radiology and Surgical Technologies underwent immunohistochemical examination for ALDH1 according to the developed protocol. Analysis of a relationship between time to metastases and ALDH1 expression showed a statistically significant decrease in time to disease progression in BC patients with high ALDH1 expression versus those with low ALDH1 expression. The similar trend was observed in overall survival. The survival of patients with less than 1 % ALDH1 expression in the cancer cells was statistically higher than that in the patients with high ALDH1 expression (more than 1 %). 

1. Weigelt B., Geyer F.C., Reis-Filho J.S. Histological types of breast cancer: how special are they? Mol Oncol 2010;4(3):192–208.

2. Li X., Lewis M.T., Huang J. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100(9):672–9.

3. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(–/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98(24):1777–85.

4. Collins A.T., Berry P.A., Hyde C. et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946–51.

5. Li C., Heidt D.G., Dalerba P. et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030–7.

6. Matsui W., Huff C.A., Wang Q. et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2332–6.

7. Al-Hajj M., Wicha M.S., BenitoHernandez A. et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983–8.

8. Morimoto K., Kim S.J., Tanei T. et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009;100:1062–8.

9. Noguchi S. Association of breast cancer stem cells identified by aldehydedehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009;15: 4234–41.

10. Tanei T., Morimoto K., Shimazu K. et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009;15:4234–41.

11. Семиглазов В.Ф. Опухоли репродуктивной системы. Клинические рекомендации по диагностике и лечению рака молочной железы. СПб., 2013. С. 149–50. [Semiglazov V.F. Reproductive system tumors. Clinical recommendations on the diagnosis and treatment of the breast cancer. SaintPetersburg, 2013. Pp. 149–50. (In Russ.)].

12. Gong C., Yao H., Liu Q. et al. Markers of tumorinitiating cells predict chemoresistance in breast cancer. PLoS One 2010;5:15630.

13. Lee H.E., Kim J.H., Kim Y.J. et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 2011;104:1730–8.

14. Sakakibara M., Fujimori T., Miyoshi T. et al. Aldehydedehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph nodepositive breast cancer. Cancer 2012;118: 3899–910.

15. Resetkova E., Reis-Filho J.S., Jain R.K. et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 2010;123:97–108.

16. Sansone P., Storci G., Tavolari S. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007;117:3988–4002.